By Josh White
Date: Wednesday 25 Jun 2025
(Sharecast News) - Scancell announced on Wednesday that it has started dosing patients in cohort four of its phase 2 'SCOPE' clinical trial, evaluating the intradermal administration and accelerated dosing of its iSCIB1+ immunotherapy for advanced unresectable melanoma.
By Benjamin Chiou
Date: Wednesday 12 Jun 2024
(Sharecast News) - Scancell Holdings saw shares surge on Wednesday after the the AIM-listed oncology immunotherapies group announced an agreement with a "major international biotechnology company".
By Josh White
Date: Tuesday 29 Aug 2023
(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.
Currency | UK Pounds |
Share Price | 10.50p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 17.50p |
52 Week Low | 7.50p |
Volume | 369,114 |
Shares Issued | 1,037.78m |
Market Cap | £108.97m |
Value | ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 1 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
15:22 | 250,000 @ 10.90p |
15:34 | 14,365 @ 10.40p |
15:21 | 4,565 @ 10.15p |
14:50 | 50,000 @ 10.60p |
13:14 | 50,184 @ 10.30p |
CFO | Sath Nirmalananthan |
CEO | Phil L'Huillier |
You are here: research